Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent Signs $45 Million Deal to Commercialize Two Lilly Oncology Drugs in China

publication date: Mar 28, 2022

Suzhou Innovent Bio acquired China commercialization rights for two Lilly oncology drugs and the right of first negotiation to a third candidate. Innovent will make $45 million in payments once the first two drugs are approved for China use. In the agreement, Innovent acquired rights to Cyramza® (ramucirumab), a China-approved gastric cancer therapy, and Retsevmo® (selpercatinib), with a China NDA for NSCLC under review. The third drug is a BTK inhibitor aimed at leukemia and lymphoma. In 2015, Lilly and Innovent formed a $1 billion partnership for Innovent’s novel drugs. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China